Contract backlog reached USD 2.3 billion, up about 15% from the prior quarter and 147% from a year earlier. Management said about 35% to 40% of it converts over the next 12 to 15 months, with a build and transfer backlog of about USD …
Research and development expense decreased USD 1.6 million in the quarter and USD 19.3 million for the nine months, while general and administrative expense increased USD 1.6 million in the quarter and USD 0.6 million for the nine months.
Net loss attributable to common stockholders was USD 19.62 million after a USD 867,000 adjustment to the carrying value of Series A Preferred Stock. Product revenue fell USD 49,000, or about 35%, to USD 91,000, and cost of product revenues was USD 28,000 against …
Management said net revenue declined 2% from the prior year to USD 145 million, better than its outlook of approximately a 5% decline and a substantial sequential improvement from the 25% decline reported in the second quarter. More than 80% of third quarter net …
Management said revenue growth reflected a 52% increase in net premiums earned and a 70% increase in policy fee income. Commission and fee revenue grew 64% to USD 75.1 million.
General and administrative expenses for the nine months rose USD 13.9 million, or 99%, from the same period of 2025, which sits alongside a net loss that was up about 63% from USD 116.4 million. Costs incurred under its 2024 agreement with Novartis are …
Every region, channel and category contributed. Direct-to-consumer sales rose 25.0% as reported to CHF 393.3 million, lifting that channel to 42.2% of sales, up 2.6 percentage points. Wholesale grew 12.2% as reported to CHF 538.2 million. Footwear rose 16%, apparel 38% and accessories 40.2%, …
Management said revenue of USD 21.6 million was a decrease of 17% from USD 26.1 million in the third quarter of 2025, and that revenue and adjusted EBITDA of USD 6.3 million both exceeded consensus expectations.
At September 30 the company held USD 161.4 million in cash, cash equivalents and marketable securities, with working capital of USD 130.1 million and an accumulatedDeficitof USD 374.5 million. Management stated the balance is sufficient to fund current operating plans for at least the …
For the nine months, net loss was USD 34.80 million, or USD 0.16 per share, against USD 7.88 million, or USD 1.38 per share. Total other income, net was USD 1.08 million against USD 54,000 for the quarter.